Ecopipam, a D1 receptor antagonist, for treatment of tourette syndrome in children: A randomized, placebo-controlled crossover study.
Donald L GilbertTanya K MurphyJoseph JankovicCathy L BudmanKevin J BlackRoger M KurlanKeith A CoffmanJames T McCrackenJorge JuncosJon E GrantRichard E ChipkinPublished in: Movement disorders : official journal of the Movement Disorder Society (2018)
Ecopipam reduced tics and was well tolerated. This placebo-controlled study of ecopipam supports further clinical trials in children and adolescents with Tourette syndrome. © 2018 International Parkinson and Movement Disorder Society.